Literature DB >> 22996653

MYC addiction: a potential therapeutic target in MM.

W Michael Kuehl1, P Leif Bergsagel.   

Abstract

In this issue of Blood, Holien et al report that MYC addiction is responsible for rapid death of myeloma cell lines and primary myeloma tumor cells treated with a specific MYC inhibitor.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22996653     DOI： 10.1182/blood-2012-08-445262

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  28 in total

1.  Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Authors:  Jagadish Kummetha Venkata; Ningfei An; Robert Stuart; Luciano J Costa; Houjian Cai; Woodrow Coker; Jin H Song; Kiwana Gibbs; Terri Matson; Elizabeth Garrett-Mayer; Zhuang Wan; Besim Ogretmen; Charles Smith; Yubin Kang
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

2.  Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.

Authors:  K T Siu; J Ramachandran; A J Yee; H Eda; L Santo; C Panaroni; J A Mertz; R J Sims Iii; M R Cooper; N Raje
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

3.  C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma.

Authors:  Sai-Qun Luo; De-Hui Xiong; Jiang Li; Guangdi Li; Yali Wang; Jia-Ming Zhang; Xiu-Fen Bu; Wei-Xin Hu; Jingping Hu
Journal:  Oncogene       Date:  2020-02-27       Impact factor: 9.867

4.  Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.

Authors:  Y Shi; Y Yang; B Hoang; C Bardeleben; B Holmes; J Gera; A Lichtenstein
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

5.  Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.

Authors:  Francesca Cottini; Teru Hideshima; Rikio Suzuki; Yu-Tzu Tai; Giampaolo Bianchini; Paul G Richardson; Kenneth C Anderson; Giovanni Tonon
Journal:  Cancer Discov       Date:  2015-06-16       Impact factor: 39.397

6.  Disruption of Lipid Raft Microdomains, Regulation of CD38, TP53, and MYC Signaling, and Induction of Apoptosis by Lomitapide in Multiple Myeloma Cells.

Authors:  Mohamed E M Saeed; Joelle C Boulos; Sabrina B Mücklich; Ellen Leich; Manik Chatterjee; Sabine M Klauck; Thomas Efferth
Journal:  Cancer Genomics Proteomics       Date:  2022 Sep-Oct       Impact factor: 3.395

7.  Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma.

Authors:  Yijiang Shi; Alan Lichtenstein; Fumou Sun; Yan Cheng; Brent Holmes; Binod Dhakal; Joseph F Gera; Siegfried Janz
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.009

Review 8.  Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.

Authors:  Takeshi Harada; Teru Hideshima; Kenneth C Anderson
Journal:  Int J Hematol       Date:  2016-04-20       Impact factor: 2.490

9.  Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.

Authors:  Deepti Soodgupta; Dipanjan Pan; Grace Cui; Angana Senpan; Xiaoxia Yang; Lan Lu; Katherine N Weilbaecher; Edward V Prochownik; Gregory M Lanza; Michael H Tomasson
Journal:  Mol Cancer Ther       Date:  2015-03-30       Impact factor: 6.261

Review 10.  Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death.

Authors:  Mélody Caillot; Hassan Dakik; Frédéric Mazurier; Brigitte Sola
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.